ONTX - Onconova Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4200
-0.0410 (-8.89%)
At close: 4:00PM EST

0.4230 0.00 (0.71%)
After hours: 5:48PM EST

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.4610
Open0.4799
Bid0.4200 x 1000
Ask0.4300 x 3000
Day's Range0.4170 - 0.4799
52 Week Range0.4170 - 5.6800
Volume577,631
Avg. Volume372,021
Market Cap2.519M
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-3.8140
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.42
  • GlobeNewswire

    Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

    Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to.

  • GlobeNewswire

    Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

    NEWTOWN, Pa., Oct. 24, 2019 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to.

  • GlobeNewswire

    Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase an aggregate of 2,136,193 shares of its common stock, at a purchase price of $1.60 per share in a registered direct offering for aggregate gross proceeds of approximately $3.4 million.  The offering is expected to close on or about September 25, 2019, subject to the satisfaction of customary closing conditions. Onconova also has agreed that for each share of common stock purchased in the offering by an investor, a corresponding number of warrants of Onconova that were issued to such investor in February 2018 and/or April 2018, as applicable, will be amended to have a reduced exercise price of $1.60 per share and the term of exercise will be extended to December 31, 2022.

  • Benzinga

    The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...

  • GlobeNewswire

    Onconova Therapeutics Announces Termination of Proposed Public Offering

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS) today announced that it has decided to terminate the public offering of shares of its common stock with the current bank previously announced in a preliminary prospectus supplement filed and supplemented September 13, 2019 and September 17, 2019 respectively. The decision to terminate results from an assessment by the Company that current equity market conditions are not conducive for an offering on terms that would be in the best interests of the Company's shareholders. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock or any other securities, and there shall not be any offer, solicitation or sale of securities mentioned in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such any state or jurisdiction.

  • GlobeNewswire

    Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), will present at the RAS-Targeted Drug Discovery Summit being held September 17-19 in Boston, Massachusetts.  Dr. Steven Fruchtman, President & CEO, will be presenting.  Also attending the conference will be Avi Oler, VP Corporate Development. There is a high frequency of Ras mutations in cancer that leads to the belief that mutations of the Ras Pathway provide a proliferative advantage and thus is involved in the pathogenesis of cancer.  As a result, targeting the Ras pathway has been the objective of scientific research for decades.  As published in the journal Cell in 2016, and now under investigation in a pivotal Phase 3 Trial, rigosertib targets the mutated RAS pathway by its interaction with Ras effector proteins containing the Ras Binding Domain.  The RAS-Targeted Drug Discovery Summit provides an opportunity to showcase the potential for rigosertib in MDS and in other RAS-driven cancers, such as KRAS-mutated lung cancer and colorectal cancer, and Ras- driven pediatric cancers as well.

  • Thomson Reuters StreetEvents

    Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT

    Q2 2019 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire

    Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results

    NEWTOWN, Pa., Aug. 14, 2019 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer,.

  • GlobeNewswire

    Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced that they have formed a collaboration to utilize the Mission Bio TapestriⓇ Platform for targeted single-cell DNA analysis to study Onconova’s novel cancer therapy, rigosertib, through clinical trials.

  • GlobeNewswire

    Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that the Company will release its second quarter financial results on August 14, 2019, before the market opens. The Company will host a conference call on August 14, 2019, at 9 a.m. Eastern Time to discuss these results. Please click here to access the webcast on the Investor Relations page of the Company’s website.

  • Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentations at the 24th Congress of the European Hematology Association being held June 13-16, 2019 in Amsterdam, Netherlands.  Dr. Steven Fruchtman, President & CEO, Dr. Ric Woodman, CMO, and Dr. Ronnee Adesanya, VP Medical Affairs, will be attending the conference.

  • Thomson Reuters StreetEvents

    Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT

    Q1 2019 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire

    Onconova Therapeutics Announces Presentations at Three Upcoming Conferences

    Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule, which the Company believes blocks cellular signaling by targeting RAS effector pathways.

  • GlobeNewswire

    Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results

    NEWTOWN, Pa., May 14, 2019 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • GlobeNewswire

    Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has entered into a license agreement for the Greater China territory with HanX Biopharmaceuticals, Inc. (HanX), a China-based pharmaceutical company focused on the development, registration, and commercialization of novel oncology products in China, to develop and commercialize rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment of higher-risk MDS (HR-MDS). Under the terms of the agreement, Onconova has granted to HanX (i) an exclusive license to develop and commercialize rigosertib in Greater China and (ii) a non-exclusive license to manufacture rigosertib in Greater China.  In exchange for these rights, HanX will make upfront payments totaling $6 million, $4 million of which are cash payments to Onconova, including a $2 million fee and an investment totaling $2 million in shares purchased at a premium to market.

  • GlobeNewswire

    Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the Company will release its first quarter 2019 financial results on Tuesday, May 14, 2019 before the market opens.  The Company will host a conference call on Tuesday, May 14, 2019, at 9 a.m. Eastern Time to discuss these results. The call will also be webcast live.  Please click here to access the webcast on the Investor Relations page of the Company’s website.  A replay will be available for 90 days. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.

  • GlobeNewswire

    Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark

    NEWTOWN, Pa., May 06, 2019 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • GlobeNewswire

    Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will be presenting at the 2019 HCW Global Life Sciences Conference at the Grosvenor House/JW Marriott Hotel in Mayfair, London.  Dr. Steven Fruchtman, President & CEO, will present at the conference and meet with investors. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. It is frequently associated with the presence of blasts or leukemic cells in the marrow.  This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions.

  • Thomson Reuters StreetEvents

    Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT

    Full Year 2018 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswire

    Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

    NEWTOWN, Pa., March 26, 2019 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule.

  • GlobeNewswire

    Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

    Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer today announced that it has surpassed the 75 percent enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE. “We are pleased to have passed the 75 percent completion of enrollment milestone and are on track with our anticipated timeline for completion of accrual to the INSPIRE study in the second half of 2019,” said Dr. Richard Woodman, Onconova’s Chief Medical Officer and Senior Vice President of Research & Development. Dr. Steven M. Fruchtman, President and CEO of Onconova, stated, “Clinical execution including completing our INSPIRE study remains our top priority.

  • GlobeNewswire

    Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will release its year-end 2018 financial results on Tuesday, March 26, 2019, before the market opens.  Management will host a conference call on Tuesday, March 26, 2019, at 9:00 a.m. Eastern Time to discuss these results and provide an update on its pipeline programs.  Interested parties may access the call by dialing toll-free (855) 428-5741 from the U.S. or (210) 229-8823 internationally and using conference ID 1878978. Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.